Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET)

AIM: To investigate the budget implications of treatment with glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus other glucose‐lowering treatment (here termed ‘standard of care’ [SoC]) during 2012‐2019. MATERIALS AND METHODS: GLP‐1 RA‐naïve adults with type 2 diabetes (T2D) in the IBM MarketScan database with at least one glucose‐lowering medication claim within 6 months after their first cardiovascular disease (CVD) hospitalization were included (index date was the date of first claim for a GLP‐1 RA for the GLP‐1 RA group, and the date of the first claim, independent of medication type, for the SoC group). Monthly healthcare costs and hospitalization risk over 12 months postindex date were compared for those who initiated a GLP‐1 RA posthospitalization versus those with a claim for any other glucose‐lowering medication. RESULTS: Postindex date, mean observed total costs were lower for patients receiving a GLP‐1 RA compared with SoC ($3853 vs. $4288). In adjusted analysis, both groups had similar total healthcare costs (P = .56). This was driven by significantly lower inpatient and outpatient costs and higher drug costs in the GLP‐1 RA group compared with SoC (P < .001). Risks of all‐cause (adjusted hazard ratio: 0.85) and CVD‐related hospitalization (0.76) were significantly lower in the GLP‐1 RA group compared with SoC (P < .001). Similar results were observed in a subgroup with atherosclerotic CVD. CONCLUSIONS: These findings suggest that, in US patients with T2D and a CVD‐related hospitalization, the added medical cost of treatment with GLP‐1 RAs is offset by lower inpatient and outpatient care costs, resulting in budget neutrality against SoC.